These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38873926)

  • 1. Associations between gut microbiota characteristics and non-motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients.
    Gorecka-Mazur A; Krygowska-Wajs A; Furgala A; Li J; Misselwitz B; Pietraszko W; Kwinta B; Yilmaz B
    Neurogastroenterol Motil; 2024 Aug; 36(8):e14846. PubMed ID: 38873926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease.
    Mueller K; Jech R; Růžička F; Holiga Š; Ballarini T; Bezdicek O; Möller HE; Vymazal J; Růžička E; Schroeter ML; Urgošík D
    Neuroimage Clin; 2018; 19():1025-1035. PubMed ID: 30035027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opposite effects of l-dopa and DBS-STN on saccadic eye movements in advanced Parkinson's disease.
    Dec-Ćwiek M; Tutaj M; Gracies JM; Volkmann J; Rudzińska M; Słowik A; Szczudlik A
    Neurol Neurochir Pol; 2017; 51(5):354-360. PubMed ID: 28669542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
    Herzog J; Möller B; Witt K; Pinsker MO; Deuschl G; Volkmann J
    Mov Disord; 2009 Jun; 24(8):1206-10. PubMed ID: 19412937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
    Dafsari HS; Martinez-Martin P; Rizos A; Trost M; Dos Santos Ghilardi MG; Reddy P; Sauerbier A; Petry-Schmelzer JN; Kramberger M; Borgemeester RWK; Barbe MT; Ashkan K; Silverdale M; Evans J; Odin P; Fonoff ET; Fink GR; Henriksen T; Ebersbach G; Pirtošek Z; Visser-Vandewalle V; Antonini A; Timmermann L; Ray Chaudhuri K;
    Mov Disord; 2019 Mar; 34(3):353-365. PubMed ID: 30719763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of indirect and direct targeted STN DBS in the treatment of Parkinson's disease-surgical method and clinical outcome over 15-year timespan.
    Lahtinen MJ; Haapaniemi TH; Kauppinen MT; Salokorpi N; Heikkinen ER; Katisko JP
    Acta Neurochir (Wien); 2020 May; 162(5):1067-1076. PubMed ID: 32103343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome?
    Merola A; Rizzi L; Zibetti M; Artusi CA; Montanaro E; Angrisano S; Lanotte M; Rizzone MG; Lopiano L
    J Neurol Neurosurg Psychiatry; 2014 May; 85(5):552-9. PubMed ID: 23847290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive timing functions of cortical beta oscillations are impaired in Parkinson's disease and influenced by L-DOPA and deep brain stimulation of the subthalamic nucleus.
    Gulberti A; Moll CK; Hamel W; Buhmann C; Koeppen JA; Boelmans K; Zittel S; Gerloff C; Westphal M; Schneider TR; Engel AK
    Neuroimage Clin; 2015; 9():436-49. PubMed ID: 26594626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eight-year follow-up outcome of subthalamic deep brain stimulation for Parkinson's disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity.
    Jiang L; Chen W; Guo Q; Yang C; Gu J; Xian W; Liu Y; Zheng Y; Ye J; Xu S; Hu Y; Wu L; Chen J; Qian H; Fu X; Liu J; Chen L
    CNS Neurosci Ther; 2021 Nov; 27(11):1366-1373. PubMed ID: 34350691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.
    Lubomski M; Xu X; Holmes AJ; Yang JYH; Sue CM; Davis RL
    J Neurol; 2022 Feb; 269(2):780-795. PubMed ID: 34128115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subthalamic deep brain stimulation improves auditory sensory gating deficit in Parkinson's disease.
    Gulberti A; Hamel W; Buhmann C; Boelmans K; Zittel S; Gerloff C; Westphal M; Engel AK; Schneider TR; Moll CK
    Clin Neurophysiol; 2015 Mar; 126(3):565-74. PubMed ID: 25085452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson's disease patients.
    Yoshida F; Miyagi Y; Kishimoto J; Morioka T; Murakami N; Hashiguchi K; Samura K; Sakae N; Yamasaki R; Kawaguchi M; Sasaki T
    Stereotact Funct Neurosurg; 2009; 87(1):45-9. PubMed ID: 19174620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease: a prospective controlled study.
    Vercruysse S; Vandenberghe W; Münks L; Nuttin B; Devos H; Nieuwboer A
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):871-7. PubMed ID: 24396010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease.
    Funkiewiez A; Ardouin C; Krack P; Fraix V; Van Blercom N; Xie J; Moro E; Benabid AL; Pollak P
    Mov Disord; 2003 May; 18(5):524-30. PubMed ID: 12722166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiota-mediated effects of Parkinson's disease medications on Parkinsonian non-motor symptoms in male transgenic mice.
    Radisavljevic N; Metcalfe-Roach A; Cirstea M; Tabusi MM; Bozorgmehr T; Bar-Yoseph H; Finlay BB
    mSphere; 2024 Jan; 9(1):e0037923. PubMed ID: 38078745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep brain stimulation improves survival in severe Parkinson's disease.
    Ngoga D; Mitchell R; Kausar J; Hodson J; Harries A; Pall H
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):17-22. PubMed ID: 23843542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson's disease.
    Atkinson-Clement C; Cavazzini É; Zénon A; Witjas T; Fluchère F; Azulay JP; Baunez C; Eusebio A
    Mov Disord; 2019 Mar; 34(3):377-385. PubMed ID: 30681186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of secondary unresponsiveness to dopaminergic drugs with preserved response to subthalamic nucleus stimulation in Parkinson's disease.
    Lenka A; Jhunjhunwala KR; Stezin A; Manjunath M; Srinivas D; Yadav R; Pal PK
    Neurol India; 2018; 66(Supplement):S135-S137. PubMed ID: 29503336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease.
    Piboolnurak P; Lang AE; Lozano AM; Miyasaki JM; Saint-Cyr JA; Poon YY; Hutchison WD; Dostrovsky JO; Moro E
    Mov Disord; 2007 May; 22(7):990-7. PubMed ID: 17443692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.